Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT01253213	BR55 in Prostate Cancer: an Exploratory Clinical Trial		Completed	No Results Available	Prostate Cancer	Drug: BR55	BR55 sensitivity assessment|BR55 specificity assessment	Bracco Diagnostics, Inc|Bracco Imaging S.p.A.	Male	40 Years and older   (Adult, Older Adult)	Early Phase 1	26	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	BR55-101	July 2010	December 2012	December 2012	December 3, 2010		April 24, 2013	AMC University Amsterdam, Amsterdam, Netherlands		https://ClinicalTrials.gov/show/NCT01253213
2	NCT03554707	SGT-53 in Children With Recurrent or Progressive CNS Malignancies		Not yet recruiting	No Results Available	Childhood CNS Tumor	Genetic: SGT-53|Radiation: Radiation|Drug: Irinotecan|Drug: Temozolomide|Drug: Bevacizumab	Incidence of Adverse Events|Response Rate|Duration of Response|Overall Survival|Progressive-Free Survival (PFS)|Characterization of Phenotype of Patients|Feasibility of Droplet PCR Assays to Monitor for Tumor Burden	SynerGene Therapeutics, Inc.	All	1 Year to 21 Years   (Child, Adult)	Early Phase 1	6	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SGT53-00-1	December 2019	December 2020	December 2021	June 13, 2018		August 5, 2019	Children's National Medical Center, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT03554707
3	NCT03564782	Examining Bioactivity of PVSRIPO in Triple Negative Breast Cancer		Recruiting	No Results Available	Triple Negative Breast Cancer	Biological: PVSRIPO	Change in tumor infiltrating immune cells	Istari Oncology, Inc.|Duke University|United States Department of Defense	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	6	Industry|Other|U.S. Fed	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Pro00085352|W81XWH-16-1-0354	June 30, 2019	July 2021	December 2021	June 21, 2018		July 4, 2019	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03564782
4	NCT03694834	Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer		Not yet recruiting	No Results Available	Endometrial Cancer|Uterine Cancer	Drug: Pembrolizumab|Procedure: Hysterectomy	Change in the number of Tumor Infiltrating Lymphocytes|Number of patients who experience Adverse Events after one dose of Pembrolizumab|Change in number of Tumor Infiltrating Lymphocytes by endometrial cancer sub-types|Correlation of Programmed Cell Death-1 (PD-1) Expression with TILs|Correlation of Immune and Obesity/Inflammation EC Signatures with TILs|Correlation of Microbiota Profiles with TILs|Overall Response Rate of Pembrolizumab with Paclitaxel and Carboplatin	UNC Lineberger Comprehensive Cancer Center|Merck Sharp & Dohme Corp.	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	LCCC 1739	December 2018	May 1, 2020	May 1, 2022	October 3, 2018		November 22, 2018			https://ClinicalTrials.gov/show/NCT03694834
5	NCT03692663	Study of Anti-PSMA CAR NK Cell in Castration-Resistant Prostate Cancer		Not yet recruiting	No Results Available	Castration-resistant Prostate Cancer	Biological: anti-PSMA CAR NK cells	Occurrence of treatment related adverse events as assessed by CTCAE v4.0	Allife Medical Science and Technology Co., Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	9	Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PSMA CAR NK-ZGZYZL-01	December 2018	December 2020	December 2021	October 2, 2018		October 2, 2018			https://ClinicalTrials.gov/show/NCT03692663
6	NCT01513356	Pharmacodynamic Study of BKM120 in Breast Cancer		Completed	No Results Available	Breast Cancer	Drug: BKM120	- To determine the grade of inhibition of PI3K/mTOR pathways, in pre-surgery setting with BKM120|Number, grade and relationship of adverse events with BKM120|Potential predictive biomarkers (PI3K mutation, KRAS, pAkt and RPS6p) for a pathologic complete response relating to BKM120	Sofia Perea, Director Clinical Trials Unit.|Novartis|Grupo Hospital de Madrid	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)	CBKM120XES01T	October 2012	February 2014	February 2014	January 20, 2012		April 2, 2014	Hospital Madrid Norte Sanchinarro- CIOCC, Madrid, Spain		https://ClinicalTrials.gov/show/NCT01513356
7	NCT03004534	A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide		Completed	No Results Available	Breast Cancer Female	Drug: darolutamide	Explore/Define Molecular Alterations in Core Tissue Tumor Samples Following Darolutamide Administration|Number of participants with treatment-related adverse events as assessed by CTCAE v4.03	Translational Research in Oncology|Bayer	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	TRIO030|2016-004151-79|HC6-24-c 201058	September 5, 2017	February 14, 2019	March 13, 2019	December 29, 2016		April 19, 2019	UCLA, Los Angeles, California, United States|Valley Breast Care and Women's Health Center, Los Angeles, California, United States|Torrance Memorial Physician Network, Cancer Care Associates, Redondo Beach, California, United States|Central Coast Medical Oncology, Santa Maria, California, United States|UF Health Cancer Center - Orlando Health, Orlando, Florida, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Hospital, Montreal, Quebec, Canada|(CIUSSS) de l'Est-de-l'Île-de-Montréal - l'Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada|Centre Hospitalier Affilie Universitaire De Quebec - Hospital Du Saint-Sacrement, Quebec City, Quebec, Canada|Universitatsklinikum Erlangen, Erlangen, Germany|Interdisziplinares Onkologisches Zentrum, Muenchen, Germany|Department of Women's Health, Tubingen, Germany		https://ClinicalTrials.gov/show/NCT03004534
8	NCT03537482	APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies		Recruiting	No Results Available	Hematologic Malignancies	Drug: APG-2575	Maximum Tolerated Dose (MTD)|Maximum plasma concentration (Cmax)|Area under the plasma concentration versus time curve (AUC)|Anti-tumor effects of APG-2575	Ascentage Pharma Group Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	90	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	APG-2575	August 7, 2018	June 15, 2019	June 15, 2020	May 25, 2018		February 19, 2019	Mayo Clinic, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Mayo Clinic, Rochester, Minnesota, United States|MDACC, Houston, Texas, United States|St. Vincent Hospital, Melbourne, Australia		https://ClinicalTrials.gov/show/NCT03537482
9	NCT01678690	An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors		Completed	No Results Available	Malignant Tumors	Drug: Gemcitabine HCl Oral Formulation	gemcitabine (dFdC) and difluorodeoxyuridine (dFdU) plasma concentration and gemcitabine triphosphate (dFdCTP) concentration in PBMC|the proportion of subjects experiencing adverse events all grades, change from baseline in clinical laboratory test results, vital sign measurements, and physical examination findings	InnoPharmax Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	11	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)	HR-11-001	August 2012	April 2014	April 2014	September 5, 2012		September 2, 2016	Georgia Regents University- Cancer Center, Augusta, Georgia, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Gabrail Cancer Center Research, Dover, Ohio, United States|National Taiwan University Hospital, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT01678690
10	NCT03692637	Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer		Not yet recruiting	No Results Available	Epithelial Ovarian Cancer	Biological: anti-Mesothelin Car NK Cells	Occurrence of treatment related adverse events as assessed by CTCAE v4.0	Allife Medical Science and Technology Co., Ltd.	Female	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	30	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Mesothelin Car NK-HNRM-01	March 2019	November 2020	November 2021	October 2, 2018		January 31, 2019			https://ClinicalTrials.gov/show/NCT03692637
11	NCT02590458	Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer		Active, not recruiting	No Results Available	Breast Cancer	Procedure: Short Breast MRI (SBMRI)|Behavioral: Questionnaire	Sensitivity of SBMRI for Detecting Breast Cancer in High Risk Participants	M.D. Anderson Cancer Center|GE Healthcare	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	131	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	2015-0243|NCI-2015-02031	October 26, 2015	October 2020	October 2021	October 29, 2015		May 23, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02590458
12	NCT02468661	A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification		Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: INC280 single agent|Drug: INC280 in combination with erlotinib|Drug: Platinum/pemetrexed	Phase Ib: Frequency and characteristics of Dose Limiting Toxicity (DLTs) to the INC280 and erlotinib combination|Phase Ib: Progression Free Survival (PFS)|Phase Ib: Overall Survival (OS)|Phase Ib: Number of patients with adverse events (AEs) as a measure of safety and tolerability|Phase Ib: Plasma concentration-time profiles of INC280 and pharmacokinetic parameters|Phase Ib: Plasma concentration-time profiles of erlotinib in the presence of INC280|Phase Ib: Disease Control Rate (DCR)|Phase Ib: Duration of Response (DOR)|Phase Ib: Progression-free Survival (PFS)|Phase Ib: Number of patients with serious adverse events as a measure of safety and tolerability	Novartis Pharmaceuticals|Novartis	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	135	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CINC280B2201	September 23, 2015	June 28, 2019	August 9, 2019	June 11, 2015		July 10, 2019	Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|University of California Irvine Medical Center Chao Family SC, Orange, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|Emory University School of Medicine/Winship Cancer Institute SC-2, Atlanta, Georgia, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital SC, Detroit, Michigan, United States|Dartmouth Hitchcock Medical Center SC, Lebanon, New Hampshire, United States|Virginia Cancer Specialists Virginia Cancer Specialists, Fairfax, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Marseille cedex 05, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Tübingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Gauting, Bayern, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Fukuoka-city, Fukuoka, Japan|Novartis Investigative Site, Akashi, Hyogo, Japan|Novartis Investigative Site, Sendai city, Miyagi, Japan|Novartis Investigative Site, Okayama-city, Okayama, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|NKI-AVL, Department of Thoracic-Oncology, Amsterdam, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Madrid, Spain		https://ClinicalTrials.gov/show/NCT02468661
13	NCT02802748	Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)		Completed	No Results Available	Breast Cancer	Drug: Oral Vinorelbine|Drug: Letrozole	Changes in the expression of the PAM50 proliferation signature upon treatment in patients defined as Luminal by PAM50|Changes in the expression of the PAM50 proliferation signature upon treatment in patients defined as Luminal by IHC and separately, in patients defined as either Luminal A or Luminal B by PAM50.|Changes in % of Ki67-positive cells (per IHC) upon treatment|Changes in the expression of angiogenic gene signature upon treatment|Changes in the expression of immune-response-related gene signature upon treatment|Changes in the expression of breast cancer related genes (contained in a 560 gene Custom CodeSet) upon treatment|Objective Response Rate (ORR) according to RECIST v1.1, assessed by ultrasound.|Safety profile	SOLTI Breast Cancer Research Group|Pierre Fabre Laboratories	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	SOLTI-1501|2015-004714-24	July 2016	January 2018	January 2018	June 16, 2016		September 20, 2018	Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital de León, León, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitari Sant Joan de Reus, Reus, Spain|Clínica Quirón Sagrado Corazón, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain		https://ClinicalTrials.gov/show/NCT02802748
14	NCT03718650	Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer		Not yet recruiting	No Results Available	Pancreatic Cancer|Resectable Pancreatic Cancer	Drug: Pimonidazole|Procedure: Surgical Resection	Radiosensitivity Index and Degree of Pimonidazole Staining|Correlative Biomarkers	H. Lee Moffitt Cancer Center and Research Institute|Varian Medical Systems	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	MCC-19599	November 1, 2019	April 1, 2021	April 1, 2022	October 24, 2018		August 7, 2019	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03718650
15	NCT03620201	M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)		Recruiting	No Results Available	Malignant Neoplasm of Breast	Drug: M7824 - patients with Stage II or III HER2+ breast cancer|Drug: Chemotherapy	change in tumor-infiltrating lymphocytes (TIL) percentage pre and post M7824 therapy|Adverse Events (AE) with M7824 Therapy|Pathological Response with M7824 Therapy	M.D. Anderson Cancer Center|EMD Serono	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0502|NCI-2018-01184	August 3, 2018	December 2019	December 2019	August 8, 2018		May 17, 2019	MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03620201
16	NCT03814447	The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer		Not yet recruiting	No Results Available	Ovarian Cancer	Drug: anti- MESO CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide	Adverse events (AEs) and Serious adverse event (SAEs)|Cmax|Tmax|AUC(0-30d)|Duration of Mesothelin-positive T cells in circulation|ORR|PFS|EORTC Quality-of-Life Questionnaire Core 15 Palliative Care (QLQ-C15-PAL) of patients after administration	Shanghai 6th People's Hospital|Hrain Biotechnology Co., Ltd.	Female	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MESO-CART	June 2019	January 2020	January 2021	January 24, 2019		May 24, 2019	Shanghai 6th People's Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03814447
17	NCT01864083	FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients		Completed	No Results Available	Breast Cancer	Procedure: Positron Emission Tomography (PET)|Drug: Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|Procedure: Positron emission mammography (PEM) When available|Procedure: MR	assess the diagnostic accuracy|ability of FACBC PET and PEM to determine therapeutic response to neoadjuvant chemotherapy	Memorial Sloan Kettering Cancer Center|GE Healthcare	Female	21 Years and older   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	11-177	May 2013	August 29, 2017	August 29, 2017	May 29, 2013		August 31, 2017	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01864083
18	NCT03392181	PET/MRI for the Staging of Newly Diagnosed Prostate Cancer		Recruiting	No Results Available	Prostate Cancer	Drug: 18F-DCFPyL	PET/MR versus mp-MRI for the Staging of Newly Diagnosed Prostate Cancer	Northwestern University|Progenics Pharmaceuticals, Inc.	Male	18 Years to 89 Years   (Adult, Older Adult)	Early Phase 1	48	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	NU 17U12|STU00205957|NCI-2018-00059	June 8, 2018	May 1, 2023	June 1, 2023	January 5, 2018		June 13, 2018	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03392181
19	NCT03263780	High Resolution PET-MRI Before Prostate Cancer HIFU		Active, not recruiting	No Results Available	Prostate Cancer	Drug: 18F-Fluciclovine	Number of biopsy-proven cancers that standard imaging (mpMRI) would have missed compared with high resolution diffusion-weighted imaging (DWI) PET-hrMRI on mapping MRI.|Negative biopsy rate|Rate of high grade cancer	Timothy J. Daskivich|Blue Earth Diagnostics|Cedars-Sinai Medical Center	Male	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	IIT2016-19-DASKIVICH-18F	December 7, 2017	December 2020	December 2020	August 28, 2017		June 20, 2019	Cedars-Sinai Medical Center, Los Angeles, California, United States	"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/80/NCT03263780/Prot_000.pdf	https://ClinicalTrials.gov/show/NCT03263780
20	NCT04011293	A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies		Recruiting	No Results Available	Relapsed or Refractory Hematological Malignancies	Biological: CNCT19	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Overall remission rate (ORR)|Response at Day 28±3 days|Percentage of patients who achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi) (partial remission，PR) at month 6 without SCT between CNCT19 infusion and Month 6 response assessment.|Percentage of patients who achieve CR or CRi (PR) with minimal residual disease negative bone marrow.|Relapse-free survival|Progression-free survival|Percentage of patients who achieve best overall response (BOR)|Duration of remission (DOR)|Overall survival|Percentage of patient who achieve CR or CRi (PR) and then proceed to stem cell transplantation（SCT） while in remission.|Proportion of patients with detectable replication competent lentivirus (RCL) by vesicular stomatitis virus, glycoprotein (VSV-G)	Shandong University|Juventas Cell Therapy Ltd.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HY001003	July 2019	July 2020	April 2022	July 8, 2019		July 8, 2019	Qilu Hospital of Shandong University, Jinan, Shandong, China		https://ClinicalTrials.gov/show/NCT04011293
21	NCT03514121	FPA150 in Patients With Advanced Solid Tumors	FPA150-001	Recruiting	No Results Available	Breast Cancer|Ovarian Cancer|Endometrial Cancer|Advanced Solid Tumors	Biological: FPA150|Biological: Pembrolizumab	For Phase 1a dose escalation, to determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of FPA150|For Phase 1a dose escalation, dose exploration and combination safety lead-in the number of participants with adverse events as assessed by the latest version of CTCAE|For Phase 1b, number of participants with adverse events as assessed by the latest version of CTCAE at the maximum tolerated dose (MTD) and/or recommended dose (RD) of FPA150|Area under serum concentration-time curve of FPA150 in day*µg/mL|Maximum serum concentration of FPA150 in µg/mL|Trough serum concentration of FPA150 in µg/mL|Clearance of FPA150 in mL/day/kg|Terminal Half-Life of FPA150 in day|Volume of distribution (mL/kg) of FPA150|Incidence of treatment emergent anti-FPA150 antibody response (levels in serum)	Five Prime Therapeutics, Inc.	All	18 Years to 99 Years   (Adult, Older Adult)	Early Phase 1	278	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	FPA150-001	March 27, 2018	January 2023	January 2024	May 2, 2018		July 24, 2019	Honor Health, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Sarcoma Oncology Research Center, Santa Monica, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Medical Oncology Associates, PS, Spokane, Washington, United States|National Cancer Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|ASAN Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03514121
22	NCT00263185	High Dose Vit D Musculoskeletal Symptoms & Bone Density in Anastrozole-Treated Breast Cancer With Marginal Vit D Status		Completed	No Results Available	Breast Neoplasms	Dietary Supplement: Vitamin D|Dietary Supplement: Calcium carbonate|Drug: Vitamin D|Other: Placebo	To compare the effects of high dose vitamin D versus standard dose vitamin D on musculoskeletal pain in breast cancer patients receiving anastrozole when vitamin D levels are in the insufficient but not deficient range (10 to 29 ng/ml).|To evaluate the prevalence of vitamin D insufficiency/deficiency in post-menopausal women with a history of breast cancer who are treated with anastrozole and have musculoskeletal symptoms versus those who are asymptomatic.|To establish correlations between levels of vitamin D, the levels of PTH, the degree of bone loss and the severity of musculoskeletal symptoms.|To evaluate the effect of standard dose versus high dose Vitamin D replacement on bone density in post-menopausal women with a history of breast cancer who are treated with anastrozole and have musculoskeletal symptoms.	Washington University School of Medicine|AstraZeneca	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	63	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care	05-0498 / 201012921	November 2005	November 2009	November 2009	December 7, 2005		September 22, 2014	Washington University, St. Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT00263185
23	NCT03291379	Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies	VEROnA	Completed	No Results Available	Carcinoma, Hepatocellular|Metastatic Colorectal Cancer	Drug: BTG-002814 (vandetanib-eluting radiopaque beads)	Adverse events (AEs) related to treatment with BTG-002814 using the National Cancer Institute- Common Terminology Criteria for Adverse Events- Version 4.0 (NCI-CTCAE v4.0)|Concentration of vandetanib and N-desmethyl vandetanib in plasma following treatment with BTG-002814|Concentration of vandetanib and N-desmethyl vandetanib in resected liver tissue following treatment with BTG-002814|BTG-002814 distribution|Evaluation of histopathological features|Assessment of changes in blood flow	Biocompatibles UK Ltd	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	8	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BTG-002814-01	May 17, 2017	April 3, 2019	April 3, 2019	September 25, 2017		July 9, 2019	University College London Hospital, Bloomsbury, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03291379
24	NCT03642496	Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies		Not yet recruiting	No Results Available	B-Cell Malignancies	Biological: Low dose ET019002- T Cells|Biological: Middle dose ET019002- T Cells|Biological: High dose ET019002- T Cells	Maximum Tolerated Dose|Tmax of serum cytokine levels|Time to baseline for serum cytokine levels|Toxicity profile of ET019002T-cell treatment|Rate of disease response|Progression free survival(PFS)|Time to baseline for B cell level	First Affiliated Hospital Xi'an Jiaotong University|Eureka Therapeutics Inc.	All	6 Years to 80 Years   (Child, Adult, Older Adult)	Early Phase 1	18	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XJTU1AF2018LSL-C003	August 19, 2018	August 19, 2020	September 20, 2020	August 22, 2018		August 23, 2018			https://ClinicalTrials.gov/show/NCT03642496
25	NCT04018053	A Pilot Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy		Not yet recruiting	No Results Available	Bladder Cancer|Urothelial Carcinoma	Drug: 18F-fluciclovine|Device: PET/CT	The agreement rate of metastatic disease status between 18F-fluciclovine-PET/CT and histopathology from radical cystectomy|The amount of 18F-fluciclovine accumulation in the primary bladder tumor on PET|The rate of detection of suspected distant metastatic disease by 18F-fluciclovine-PET/CT|18F-fluciclovine uptake on PET/CT to the presence/absence of ASCT2 and LAT1 amino acid transporters.	Dana-Farber Cancer Institute|Blue Earth Diagnostics	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	16	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	19-208	August 31, 2019	December 31, 2021	December 31, 2021	July 12, 2019		July 12, 2019	Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT04018053
26	NCT02204943	Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer		Completed	No Results Available	Bone Metastatic Castration-Resistant Prostate Cancer	Device: Biomarker analysis|Drug: Administration of radium-223	Proportion of patients who overexpress alkaline phosphatase (ALP) in Circulating Tumor Cells (CTCs) at each time point|Change in biomarkers of epithelial plasticity and osteomimicry expressed in the bone metastases of men with bone metastatic CRPC	Duke University|Bayer	Male	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	Pro00053925	May 6, 2015	July 31, 2017	July 31, 2017	July 31, 2014		June 8, 2018	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02204943
27	NCT00331630	Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer		Active, not recruiting	No Results Available	Breast Cancer	Drug: lapatinib ditosylate|Drug: paclitaxel albumin-stabilized nanoparticle formulation	Clinical response rate as measured by clinical exam and imaging studies|Pathologic complete response rate|Correlation of proliferation (Ki67) with tumor response as measured at baseline and after completion of study treatment|Correlation of apoptosis (cleaved caspase-3) with tumor response as measured at baseline and after completion of study treatment|Correlation of angiogenesis (vW, CD34) markers with tumor response as measured at baseline and after completion of study treatment|Correlation of other studies with tumor response, including epidermal growth factor receptor (EGFR), HER2/neu, matrix metalloproteinases (MMPs), and transforming growth factor (TGF-β) as measured at baseline and after completion of study treatment|Side effects from the combination of Abraxane and Lapatinib|Circulating tumor cell measurement	Northwestern University|GlaxoSmithKline|Celgene Corporation	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 05B2|STU00007257	May 2006	August 2014	August 2021	May 31, 2006		May 3, 2019	Northwestern University, Northwestern Medical Faculty Foundation, Chicago, Illinois, United States|Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States|Midwest Center for Hematology/Oncology, Joliet, Illinois, United States|Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields, Olympia Fields, Illinois, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States		https://ClinicalTrials.gov/show/NCT00331630
28	NCT03802604	Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer	PROMETEO	Recruiting	No Results Available	Breast Cancer	Biological: Talimogene laherparepvec|Drug: Atezolizumab	Changes in the expression of a gene signature tracking activated CD8 T-cells.|Rate of pCRB (ypT0/Tis) and pCRBL (ypT0/TisypN0)|Tumor ORR|Rate of residual cancer burden (RCB)|Safety of T-VEC in combination with atezolizumab	SOLTI Breast Cancer Research Group|Amgen|Roche Pharma AG	Female	18 Years to 99 Years   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	SOLTI-1503	December 10, 2018	November 2020	November 2023	January 14, 2019		January 21, 2019	Hospital Universitari Vall d'Hebrón, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Clínico universitario de Valencia, Valencia, Spain		https://ClinicalTrials.gov/show/NCT03802604
29	NCT00140556	Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer		Completed	Has Results	Head and Neck Cancer|Pharynx Cancer	Radiation: Chemoradiotherapy|Drug: Cisplatin|Drug: Bevacizumab|Drug: Erlotinib	Tumor Resolution|Local Regional Control|Failure Free Survival	David M. Brizel, MD|Genentech, Inc.|OSI Pharmaceuticals|Duke University	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	28	Other|Industry	Interventional	Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00008840|7077	August 2005	May 2009	April 2010	September 1, 2005	August 31, 2011	January 18, 2013	Department of Radiation Oncology; Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00140556
30	NCT03085056	Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer		Recruiting	No Results Available	Anaplastic Thyroid Cancer	Drug: Trametinib|Drug: Paclitaxel	Progression-Free Survival (PFS)	Memorial Sloan Kettering Cancer Center|Novartis	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-055	March 15, 2017	September 2020	September 2020	March 21, 2017		May 6, 2019	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03085056
31	NCT03215095	RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers		Recruiting	No Results Available	Thyroid Cancer	Drug: Durvalumab (Medi4736)|Radiation: Radioiodine (RAI)	number of patients with Dose-Limiting Toxicity (DLTs)|Best Overall Response	Memorial Sloan Kettering Cancer Center|AstraZeneca|MedImmune LLC	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	11	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-218	July 10, 2017	July 2020	July 2020	July 12, 2017		August 7, 2019	Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States		https://ClinicalTrials.gov/show/NCT03215095
32	NCT03815630	A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors	DC-CIK	Not yet recruiting	No Results Available	Solid Tumor	Drug: pd-1 and dc-cik cells	occurrence of treatment related adverse events	Allife Medical Science and Technology Co., Ltd.|The First People's Hospital of Yunnan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital|Henan Provincial Hospital|Beijing Hospital	All	18 Years to 60 Years   (Adult)	Early Phase 1	100	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	PD-1/DC CIK-YNYY-01	February 1, 2019	February 1, 2020	February 1, 2021	January 24, 2019		January 30, 2019			https://ClinicalTrials.gov/show/NCT03815630
33	NCT03815084	A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors		Not yet recruiting	No Results Available	Solid Tumor	Drug: pd-1 and DC-NK cells	occurrence of treatment related adverse events	Allife Medical Science and Technology Co., Ltd.|The First People's Hospital of Yunan Province/First People's Hospital of Yunan Provinve New Kunhua Hospital|Henan Provincial Hospital|Beijing Hospital	All	18 Years to 60 Years   (Adult)	Early Phase 1	100	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research	PD-1/DC-NK YNYY-01	February 1, 2019	February 1, 2020	February 1, 2021	January 24, 2019		January 30, 2019			https://ClinicalTrials.gov/show/NCT03815084
34	NCT00606424	An Exploratory, Open Label, Single Center Study of [F-18]HX4	HX4	Completed	No Results Available	Head and Neck Cancer	Drug: 20 mCi dose for a 50 kg individual of [F-18]HX4	Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.	Siemens Molecular Imaging	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	10	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	DHX4000	January 2008	January 2009	January 2009	February 4, 2008		February 2, 2009	Michael Yu, MD, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00606424
35	NCT01189643	Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor		Active, not recruiting	No Results Available	Sarcoma|Desmoplastic Small Round Cell Tumor (DSRCT)	Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator	To define the tolerability|To define adverse event profile|To estimate the response rate of two cycles of irinotecan, temozolomide and bevacizumab|To estimate survival|To estimate time to progression|To assess use of 18FDG PET-CT	Memorial Sloan Kettering Cancer Center|Genentech, Inc.	All	1 Year to 29 Years   (Child, Adult)	Early Phase 1	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-091	August 2010	August 2019	August 2019	August 26, 2010		September 5, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01189643
36	NCT03691311	Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer	D-BIOMARK	Recruiting	No Results Available	Breast Neoplasm Female|Stage I Breast Cancer|Stage II Breast Cancer|Hormone Receptor Negative Neoplasm|Hormone Receptor Positive Tumor	Drug: Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]	Antiproliferative and/or pro-apoptotic activity of denosumab|Correlation between antiproliferative activity of denosumab and Rank/RankL expression|Differential antiproliferative activity of denosumab among the different phenotypes of breast cancers.|Differential antiproliferative activity of denosumab among pre and post menopausal patients|Safety of denosumab and biopsy procedures in terms of Frequency of adverse events (CTCAE V4.)	Institut Català d'Oncologia|Amgen	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICO 13-001|2016-002678-11|20119112	July 5, 2018	July 5, 2020	February 5, 2021	October 1, 2018		August 7, 2019	Institut Català d'Oncologia - L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, Spain		https://ClinicalTrials.gov/show/NCT03691311
37	NCT03433898	This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer		Recruiting	No Results Available	Neoplasms	Drug: BI 754091|Drug: BI 754111	Part I: Maximum tolerated dose (MTD) of BI 754091|Part I: Number of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period (first cycle of treatment)|Part II: MTD of the BI 754091 plus BI 754111 combination|Part II: Number of patients experiencing DLTs during the MTD evaluation period (first cycle of treatment)|Part III: Objective response (OR) - confirmed complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumours (RECIST) Version 1.1 as assessed by the Investigator|Part I: Cmax: maximum measured concentration of BI 754091 in plasma|Part I: AUC0-504: area under the concentration-time curve of BI 754091 in plasma|Part II: Cmax: maximum measured concentration of BI 754091 and BI 754111 in plasma|Part II: AUC0-504: area under the concentration-time curve of BI 754091 and BI 754111 in plasma|Part III: Duration of response|Part III: Disease control|Part I - Objective response (OR)|Part II - Objective response (OR)	Boehringer Ingelheim	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	164	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1381-0004	February 23, 2018	April 18, 2021	April 18, 2021	February 15, 2018		August 7, 2019	Kanagawa Cancer Center, Kanagawa, Yokohama, Japan|Saitama Cancer Center, Saitama, Kitaadachi-gun, Japan|Shizuoka Cancer Center, Shizuoka, Sunto-gun, Japan|National Cancer Center Hospital, Tokyo, Chuo-ku, Japan|Jananese Foundation for Cancer Research, Tokyo, Koto-ku, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT03433898
38	NCT03143270	A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer		Recruiting	No Results Available	Liver Cancer	Drug: Drug Eluting Bead Transarterial Chemoembolization|Drug: Nivolumab	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	14	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-087	April 28, 2017	April 2020	April 2020	May 8, 2017		April 24, 2019	Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03143270
39	NCT02728830	A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers		Active, not recruiting	No Results Available	Gynecologic Neoplasms|Epithelial Ovarian Cancer|Uterine Endometrial Cancer|Fallopian Tube Cancer|Peritoneal Cancer	Drug: Pembrolizumab	Fold change in tumor Immune Infiltrates|Toxicity Profile: Frequency and severity of adverse events as assessed by CTCAE	AA Secord|Merck Sharp & Dohme Corp.|Duke University	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00068544	June 2016	November 2019	April 2020	April 5, 2016		May 27, 2019	Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Duke Cancer Institute, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT02728830
40	NCT03965546	ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer		Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasms|Metastatic Liver Cancer	Combination Product: Sorafenib combined with ET140202-T cell|Combination Product: TAE combined with ET140202-T cell|Biological: ET140202-T cell	Frequency of ARTEMIS T cell treatment-related adverse events|Rate of disease response by RECIST in the liver|Rate of disease response by RECIST at non-liver sites|Progression free survival (PFS)|Median Survival（MS）|Overall survival（OS）|AFP serum levels|Number of ET140202-T cells in peripheral blood|Alpha-fetoprotein (AFP) expression in tumors|IL-6 serum levels|IL-2 serum levels|IL-10 serum levels|TNF-α serum levels|IFN-γ serum levels	First Affiliated Hospital Xi'an Jiaotong University|Eureka Therapeutics Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Early Phase 1	27	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2019（ZD13）	May 30, 2019	June 2021	June 2022	May 29, 2019		August 8, 2019	The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China		https://ClinicalTrials.gov/show/NCT03965546
41	NCT03592121	Study to Investigate the Effect of AB-101 in Breast Cancer Survivors		Recruiting	No Results Available	Sexual Dysfunction|Sexual Arousal Disorder|Sexual Dysfunction, Physiological|Breast Cancer|Nipple Disorder|Neuropathy|Cancer of Breast	Drug: AB-101|Drug: Placebo	Delayed Orgasm|Vaginal Dryness	Applied Biology, Inc.	Female	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	35	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	RJ-101-RCT-001	July 9, 2018	November 12, 2019	November 12, 2019	July 19, 2018		October 5, 2018	Southern CA Center for Sexual Health and Survivorship Medicine, Newport Beach, California, United States		https://ClinicalTrials.gov/show/NCT03592121
42	NCT03837821	(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer	CLONEVO	Recruiting	No Results Available	Bladder Cancer	Drug: Abemaciclib	Change in cell-cycle dynamics between pre- and post-Abemaciclib tumor samples assessed by immunohistochemistry of tumor tissues, circulating tumor DNA (ctDNA)|Incidence of Treatment-Emergent Adverse Events (TEAEs) of Abemaciclib assessed by CTCAE 4.0|Effect on tumor downstaging defined as <pT2 at time of cystectomy	Weill Medical College of Cornell University|Eli Lilly and Company	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1710018693	February 5, 2019	February 2021	February 2022	February 12, 2019		July 23, 2019	Weill Cornell Medicine, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03837821
43	NCT03371992	Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC	NO3DEXPL	Enrolling by invitation	No Results Available	Non Small Cell Lung Cancer	Drug: Nivolumab|Diagnostic Test: 3D-EX|Other: Evaluation of Response by RECIST	Evaluation of target lesions by RECIST	Nilogen Oncosystems|Henry Ford Health System	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	25	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	NO88352235	March 9, 2018	December 2019	June 2020	December 13, 2017		March 13, 2019	Henry Ford Health Systems, Detroit, Michigan, United States		https://ClinicalTrials.gov/show/NCT03371992
44	NCT03890198	A Phase 1 Study of LCAR-C182A/LCAR-C182B/LCAR-C182C Cells,a Chimeric Antigen Receptor T-cell (CAR-T)		Recruiting	No Results Available	Gastric Cancer|Pancreatic Ductal Adenocarcinoma	Biological: LCAR-C182A/LCAR-C182B/LCAR-C182C cells	Number of Participants With Adverse Events|Transgene Levels of LCAR-C82 CAR-T Cells|Chimeric Antigen Receptor T (CAR-T) Positive Cell Concentration|Systemic Cytokine Concentrations|Overall Response Rate (ORR)|Duration of Overall Response(DOR)|progression-free survival(PFS)|Overall Survival (OS)	First Affiliated Hospital Xi'an Jiaotong University|Nanjing Legend Biotech Co.	All	18 Years to 75 Years   (Adult, Older Adult)	Early Phase 1	18	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MO-GPC01	April 22, 2019	March 31, 2023	December 31, 2023	March 26, 2019		May 7, 2019	The First Affiliated Hospital of Xian Jiaotong University, Xi'an, Shanxi, China		https://ClinicalTrials.gov/show/NCT03890198
45	NCT00360152	Testing of Different Methods for Determining Whether Breast Cancer Has Spread to the Lymph Nodes		Completed	No Results Available	Breast Neoplasms	Procedure: Fine needle aspiration biopsy (FNAB)|Procedure: Sentinel Lymph Node Biopsy	Determine the sensitivity of AUS and real-time RT-PCR/RT-LAMP to predict the pathologic status of the axilla in breast cancer patients|Determine the feasibility of AUS, FNAB, and RT-PCR/RT-LAMP as an alternative to SLNB for axillary staging of breast cancer patients|Define baseline gene expression levels in lymph nodes by RT-PCR/RT-LAMP in patients with no evidence of malignancy undergoing procedures under general anesthesia	Washington University School of Medicine|Society for Surgical Oncologists|Sysmex America, Inc.	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	100	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	06-0530 / 201109077	August 2006	January 2009	April 2013	August 3, 2006		July 4, 2013	Washington University School of Medicine, St. Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT00360152
46	NCT03799913	MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer		Recruiting	No Results Available	Ovarian Cancer	Biological: anti-MESO CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide	Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0|Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm|Progress Free Survival (PFS) after administration|Duration of CAR-positive T cells in circulation|Detection of PD1 antibody in serum	Zhejiang University|Second Affiliated Hospital, School of Medicine, Zhejiang University|Hrain Biotechnology Co., Ltd.	Female	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MESO	April 10, 2019	October 2021	April 2022	January 10, 2019		April 10, 2019	The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China		https://ClinicalTrials.gov/show/NCT03799913
47	NCT03795779	CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies		Recruiting	No Results Available	Hematologic Malignancy|Acute Myeloid Leukemia|Myelodysplastic Syndromes|Myeloproliferative Neoplasm|Chronic Myeloid Leukemia	Biological: CLL1-CD33 cCAR T cells	Number of participants with dose limiting toxicity (DLT) as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0|Type of dose-limiting toxicity (DLT)|Number of participants with adverse event by severity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0|Overall Response Rate (ORR)|Progression-free survival (PFS)|Overall survival	iCell Gene Therapeutics|The General Hospital of Western Theater Command|iCAR Bio Therapeutics Ltd	All	Child, Adult, Older Adult	Early Phase 1	20	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICG141-001	March 1, 2018	September 30, 2020	September 30, 2020	January 8, 2019		May 9, 2019	The General Hospital of Western Theater Command, Chengdu, China|Peking University Shenzhen Hospital, Shenzhen, China		https://ClinicalTrials.gov/show/NCT03795779
48	NCT00583063	Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers		Completed	No Results Available	Solid Tumors	Drug: sunitinib|Drug: rapamycin	Pharmacokinetic interactions|Toxicity of the combined drug regimen|Response to drug regimen	University of Chicago|Pfizer	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	23	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15328B	October 2007	April 2008	April 2008	December 31, 2007		June 12, 2013	University of Chicago, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT00583063
49	NCT03863145	Study to Evaluate Maximum Tolerated Dose of Oral CB-03-10 With Dose Expansion Phase, in Advanced Solid Tumors		Not yet recruiting	No Results Available	Advanced Refractory Solid Tumors|Subjects Considered Likely to Respond to CB-03-10	Drug: CB-03-10	Determine the maximum tolerated dose|Determine the dose-limiting toxicity|Determine a recommended Phase 2 dose (RP2D) of CB-03-10|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Evaluate the activity response rate|Cmax of CB-03-10|AUC of CB-03-10|Cmax of CB-03-10 metabolite CB-03-05|AUC of CB-03-10 metabolite CB-03-05|Evaluate the activity overall survival [OS]|Evaluate the activity progression-free survival [PFS]	Cosmo Technologies Ltd	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	90	Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CB-03-10/01	July 2019	November 2019	December 2019	March 5, 2019		March 5, 2019			https://ClinicalTrials.gov/show/NCT03863145
50	NCT02338037	Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors		Active, not recruiting	No Results Available	Metastatic Malignant Neoplasm in the Adult Brain|Primary Brain Tumor	Procedure: Therapeutic Conventional Surgery|Procedure: Biopsy|Drug: Eribulin Mesylate|Procedure: Microdialysis|Other: Pharmacological Study	Time of maximum concentration observed (Tmax) for eribulin mesylate|Maximum concentration observed (Cmax) for eribulin mesylate|Area under the curve (AUC) for eribulin mesylate|Half-life (t1/2) for eribulin mesylate|Ratio of AUC of eribulin mesylate in dialysate to plasma|Toxicity profile of eribulin mesylate graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Clinical benefit rate defined as tumor response on brain MRI results	City of Hope Medical Center|National Cancer Institute (NCI)|Eisai Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	8	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14312|NCI-2014-02391	May 19, 2015	September 2019	September 2019	January 14, 2015		October 9, 2018	City of Hope Medical Center, Duarte, California, United States		https://ClinicalTrials.gov/show/NCT02338037
51	NCT01875666	Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib		Active, not recruiting	No Results Available	Breast Neoplasms	Drug: Trastuzumab|Drug: pertuzumab|Drug: lapatinib	difference in kinome activation pre and post treatment|predictability in kinome activation	UNC Lineberger Comprehensive Cancer Center|Genentech, Inc.|Susan G. Komen Breast Cancer Foundation|GlaxoSmithKline	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	LCCC 1214	September 2013	December 2016	March 2019	June 12, 2013		November 2, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|IU Simon Cancer Center, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|MD Anderson, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01875666
52	NCT03162731	Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer		Active, not recruiting	No Results Available	Larynx|Lip, Oral Cavity and Pharynx	Biological: Nivolumab|Biological: Ipilimumab|Radiation: Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Radiation: Volume Modulated Arc Therapy	Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events version 4.03	Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.082	May 11, 2017	November 2021	January 2022	May 22, 2017		August 2, 2019	Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03162731
53	NCT00718770	A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression		Completed	Has Results	Thyroid Cancer	Drug: Bexarotene	Change in Tumor Size	University of Colorado, Denver|American Cancer Society, Inc.|Eisai Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07-0727.cc	November 2008	January 2013	February 2013	July 21, 2008	January 17, 2014	January 17, 2014	University of Colorado Cancer Center, Aurora, Colorado, United States		https://ClinicalTrials.gov/show/NCT00718770
54	NCT02172651	Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.		Recruiting	No Results Available	Stage, Colon Cancer|Stage I-III Colon Cancer|Stage IV Colon Cancer With Resectable Liver Metastases	Drug: Vitamin D3	VDR Binding Sites|RNA transcriptome|Number of Participants with Serious and Non-Serious Adverse Events	Dana-Farber Cancer Institute|National Cancer Institute (NCI)|Pharmavite	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	12	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	14-091|P50CA127003-06A1	July 2014	December 2019	May 2020	June 24, 2014		July 3, 2019	Dana-Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02172651
55	NCT01329718	Specimens for Septin 9 Performance	SPR0012	Completed	No Results Available	Colorectal Cancer	Other: Blood Sample	Effectiveness of the Epi proColon test	Epigenomics, Inc	All	50 Years and older   (Adult, Older Adult)	Early Phase 1	562	Industry	Interventional	Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic	Epigenomics_SPR0012	May 2011	December 2012	December 2012	April 6, 2011		August 4, 2014			https://ClinicalTrials.gov/show/NCT01329718
56	NCT03361800	Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC		Recruiting	No Results Available	Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer	Drug: Entinostat	Decrease in Ki-67 mRNA following treatment with entinostat across TNBC breast cancers|mRNA gene expression changes following treatment with entinostat, across TNBC|Changes in the proliferation signature by mRNA expression following treatment with entinostat across TNBC|Differential kinome activation before and after treatment with entinostat across TNBC|Correlation of mutation and/or copy number variations by whole exome sequencing (WES) with mRNA gene expression changes and reduction of proliferation signature following treatment with entinostat across TNBC.|Correlation of protein lysine hyperacetylation in peripheral blood and tumor from pre- and post-entinostat treated TNBCs|Percentage of participants with treatment related adverse events	UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	LCCC 1639|P50CA058223	November 28, 2018	January 15, 2020	February 15, 2020	December 5, 2017		April 16, 2019	Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03361800
57	NCT01676792	SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma		Completed	No Results Available	Vulvar Intraepithelial Neoplasia|Genital Warts	Drug: SR-T100 gel with 2.3% of SM in Solanum undatum plant extract	Patients achieve greater than or equal to 75% lesion size reduction|Total clearance rate|Partial clearance rate	National Cheng-Kung University Hospital|G&E Herbal Biotechnology Co., LTD	All	20 Years and older   (Adult, Older Adult)	Early Phase 1	29	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	100CT221	April 2011	April 2013	October 2013	August 31, 2012		April 22, 2014	National Cheng Kung University Hospital, Tainan, Taiwan		https://ClinicalTrials.gov/show/NCT01676792
58	NCT01467310	Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212		Completed	No Results Available	Breast Cancer	Drug: GSK1120212	the number and type of kinases in participant tissue sample prior to administration of drug compared to post-treatment.|the number and type of kinases that produce a compensatory response to MEK inhibitor|the number of participants with adverse events	UNC Lineberger Comprehensive Cancer Center|GlaxoSmithKline|National Cancer Institute (NCI)|Susan G. Komen Breast Cancer Foundation	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	15	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	LCCC 1122|11-1689|CA058223	January 2012	April 2016	April 2016	November 8, 2011		March 13, 2017	Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT01467310
59	NCT00405366	Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer	NRR	Completed	No Results Available	Kidney Cancer	Drug: sorafenib tosylate	Number of subjects experiencing adverse events while taking sorafenib prior to nephrectomy|Feasibility of neoadjuvant systemic therapy prior to nephrectomy|Response in primary renal tumors|Effects of sorafenib tosylate therapy on gene expression, protein expression, and metabolic profile	UNC Lineberger Comprehensive Cancer Center|Doris Duke Charitable Foundation|Bayer|Amgen	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LCCC 0603|CDR0000550127	November 2006	June 2009	July 2015	November 30, 2006		April 18, 2017	Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00405366
60	NCT02826382	Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041		Recruiting	No Results Available	Prostate Cancer|Bone Metastases	Drug: [68Ga]P15-041	Time course of uptake of [68Ga]P15-041 in bone metastases|Time course of whole body distribution of [68Ga]P15-041	Five Eleven Pharma, Inc.	Male	18 Years and older   (Adult, Older Adult)	Early Phase 1	30	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	511-0001-A	September 20, 2016	December 2019	March 2020	July 11, 2016		April 4, 2019	University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02826382
61	NCT00427752	Abdominal Exploration Without Incisions		Completed	No Results Available	Pancreatic Cancer	Procedure: Transgastric endoscopic peritoneoscopy.	1) That transgastric endoscopic peritoneoscopy is feasible.|That bacterial abdominal contamination is not clinically significant.	Jeffrey Hazey|Stryker Nordic|Ethicon Endo-Surgery|Ohio State University	All	18 Years to 80 Years   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic	2006H0120	October 2006	January 2012	January 2012	January 29, 2007		May 7, 2012	The Ohio State University Center for Minimally Invasive Surgery, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT00427752
62	NCT03575598	Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study	SNOW	Recruiting	No Results Available	Squamous Cell Carcinoma, Head And Neck|Squamous Cell Carcinoma Mouth|Squamous Cell Carcinoma of the Oral Cavity	Drug: Sitravatinib|Biological: Nivolumab	Pharmacodynamic effects with biomarker analyses|Immune effects with biomarker analyses|Toxicities as per NCI CTCAE v5.0|Rate of completion of surgery within the initially planned window|Rate of post-operative complications|Rate of disease progression as per RECIST v1.1 during the pre-operative treatment period|Pathologic treatment effect in tumor and/ or lymph nodes|Rate of nodal extracapsular extension and positive margins|Analysis of plasma Sitravatinib concentration before and after Nivolumab therapy	University Health Network, Toronto|Mirati Therapeutics Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SNOW-001	August 30, 2018	August 30, 2020	August 30, 2020	July 2, 2018		September 5, 2018	Princess Margaret Cancer Centre, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03575598
63	NCT03153410	Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas		Recruiting	No Results Available	Pancreatic Cancer	Drug: Cyclophosphamide|Drug: GVAX|Drug: Pembrolizumab|Drug: IMC-CS4	CD8 T cell density in the primary tumor after neoadjuvant administration of combination immunotherapy by immunohistochemistry (IHC)|Number of participants experiencing study drug-related toxicities|Overall survival (OS)|Disease free survival (DFS)|Objective response rate (ORR) by immune-related RECIST criteria (irRC)|Surgical resectability rate of borderline resectable pancreatic cancer (BRPC)|Pathologic response rate of patients with BRPC|Progression free survival (PFS)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Merck Sharp & Dohme Corp.|Eli Lilly and Company	All	18 Years to 100 Years   (Adult, Older Adult)	Early Phase 1	12	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1766|IRB00130267	September 7, 2018	September 2020	September 2020	May 15, 2017		March 19, 2019	Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03153410
64	NCT03473730	Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer		Recruiting	No Results Available	Bladder Urothelial Carcinoma|Clear Cell Renal Cell Carcinoma|Malignant Urinary System Neoplasm|Metastatic Kidney Carcinoma|Stage IV Renal Cell Cancer AJCC v8	Procedure: Biopsy|Biological: Daratumumab|Other: Laboratory Biomarker Analysis|Procedure: Metastasectomy|Procedure: Nephrectomy	Incidence of adverse events|Rate of surgical delay (Bladder cohort)|Incidence of surgical complications (Bladder cohort)|Pathologic response (Bladder cohort)|Best objective response rate (ORR) (Renal cohort)|Progression-free survival (PFS) (Renal cohort)	M.D. Anderson Cancer Center|Janssen Research & Development, LLC|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	30	Other|Industry|NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0688|NCI-2018-00800|P30CA016672	May 29, 2018	December 31, 2021	December 31, 2021	March 22, 2018		May 2, 2019	M D Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03473730
65	NCT03735095	Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer		Not yet recruiting	No Results Available	Locally Advanced Lung Carcinoma|Non-Small Cell Lung Carcinoma|Small Cell Lung Carcinoma|Stage III Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8|Stage IIIB Lung Cancer AJCC v8|Stage IIIC Lung Cancer AJCC v8	Drug: Porfimer Sodium|Procedure: Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy	Incidence of adverse events that are >= grade 4 according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0|Tumor response rate|Progression-free survival (PFS) assessed using modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria	Roswell Park Cancer Institute|National Cancer Institute (NCI)|Pinnacle Biologics Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	6	Other|NIH|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I 279415|NCI-2018-01969|P30CA016056	August 1, 2019	October 1, 2019	November 15, 2020	November 8, 2018		July 16, 2019	Roswell Park Cancer Institute, Buffalo, New York, United States		https://ClinicalTrials.gov/show/NCT03735095
66	NCT03655756	pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma		Recruiting	No Results Available	Cutaneous Melanoma, Stage III|Cutaneous Melanoma, Stage IV	Biological: IFx-Hu2.0	Safety; defined as four of the six patients enrolled having no grade-3 or higher treatment-related adverse events as assessed by CTCAE v5.0.|Feasibility; defined as the ability to treat at least five of the six patients enrolled without dose-limiting toxicity.|Objective response rate (ORR) determined using standard criteria.	Morphogenesis, Inc.|H. Lee Moffitt Cancer Center and Research Institute	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	6	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CM 2017-01	November 5, 2018	September 2019	November 2019	August 31, 2018		February 6, 2019	H. Lee Moffitt Cancer Center, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03655756
67	NCT02113657	T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer		Active, not recruiting	No Results Available	Prostate Cancer	Drug: Ipilimumab	Impact of Ipilimumab on T Cell Responses to prostate cancer neoantigens in both primary tumor and metastatic sites in men with metastatic CRPC	M.D. Anderson Cancer Center|Bristol-Myers Squibb|Stand Up To Cancer|High Impact Clinical Research Support Program	Male	18 Years and older   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2013-0444|NCI-2014-01205|SUC2CR-AACR-DT10	August 20, 2014	August 2019	August 2020	April 14, 2014		May 20, 2019	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02113657
68	NCT01380795	Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas	CTC-Poumon	Completed	No Results Available	Non-small Cell Lung Cancer Metastatic	Biological: CTC	search for the mutation of EGFR and Kras in the CTC of the patient|Compare EGFR/ K-ras status between CTC and the primitive tumor|Monitoring of the mutations of EGFR / K-ras in the CTC of the patients during treatment	Centre Georges Francois Leclerc|AstraZeneca	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	0416-1cobr10	March 2011	February 2013		June 27, 2011		March 26, 2015	Centre Georges François Leclerc, Dijon, France		https://ClinicalTrials.gov/show/NCT01380795
69	NCT03477110	Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma		Recruiting	No Results Available	Glioblastoma	Drug: Temozolomide|Radiation: Radiation Therapy|Device: NovoTTF-200A Device|Procedure: Tumor Treating Fields Therapy	NovoTTF-200A device discontinuation rate due to skin toxicity|Progression-free survival|Overall survival|Event-free survival	Sidney Kimmel Cancer Center at Thomas Jefferson University|NovoCure Ltd.|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.346	May 4, 2018	September 2019	September 2020	March 26, 2018		May 20, 2019	Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03477110
70	NCT00864864	Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma		Completed	No Results Available	Glioblastoma|Brain Tumor	Drug: Sunitinib	To assess the ability of sunitinib to achieve a target tumor: plasma ration greater than or equal to 0.2 in patients with recurrent GM.|To determine if there is an association between growth factor receptor inhibition and tumor phenotype, tumor: plasma ratio of sunitinib and overall survival.	Massachusetts General Hospital|Brigham and Women's Hospital|Dana-Farber Cancer Institute|Pfizer	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	8	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	06-307	May 2007	May 2011	May 2013	March 19, 2009		July 7, 2016	Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00864864
71	NCT03158883	UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients		Recruiting	No Results Available	Metastatic Non-small Cell Lung Cancer (NSCLC)	Drug: Avelumab|Radiation: Stereotactic ablative radiotherapy (SAR)	Overall Response Rate|Overall Survival (OS)|Progression-Free Survival (PFS)|Disease Control Rate (DCR)|Duration of Stable Disease|Duration of Overall Response|Confirmation|Immune Related Response Criteria|Evaluation of Best Overall Response	Megan Daly, MD|EMD Serono|University of California, Davis	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	26	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1054028|UCDCC#270	May 17, 2017	June 1, 2020	June 1, 2021	May 18, 2017		May 1, 2019	UC Davis, Sacramento, California, United States		https://ClinicalTrials.gov/show/NCT03158883
72	NCT02652455	Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma		Active, not recruiting	No Results Available	Melanoma (Skin)|Skin Cancer	Drug: Nivolumab|Procedure: Surgery to Remove Tumor for Growth of TIL|Drug: CD137|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: TIL Infusion|Drug: Interleukin-2	Occurrence of Study Related Adverse Events	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Prometheus Inc.|Iovance Biotherapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	11	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-18377	March 2, 2016	August 2019	August 2020	January 11, 2016		May 6, 2019	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT02652455
73	NCT03888859	ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma		Recruiting	No Results Available	Hepatocellular Carcinoma|Liver Cancer|Liver Neoplasms|Metastatic Liver Cancer	Biological: ET1402L1-ARTEMIS™ T cells -IV|Biological: ET1402L1-ARTEMIS™ T cells -intra-hepatic artery|Biological: ET1402L1-ARTEMIS™ T cells -Intratumoral Injections	Number of patients with dose-limiting toxicity|Frequency of ARTEMIS T cell treatment-related adverse events|Rate of disease response by RECIST in the liver|Rate of disease response by RECIST at non-liver sites|Progression free survival (PFS)|Median Survival（MS）|Overall survival（OS）|AFP serum levels|Number of ET1402L1-ARTEMIS™2 T cells in peripheral blood|% of ET1402L1-ARTEMIS™2 T cells in peripheral blood|AFP expression in tumors|Tmax of serum Interleukin (IL)-2, IL-4, IL-6, IL-10, Tumor necrosis factor(TNF)-α and Interferon gamma (INFγ)|AUC of serum IL-2, IL-4, IL-6, IL-10, TNF-α and INFγ|Time to baseline for serum IL-2, IL-4, IL-6, IL-10, TNF-α and INFγ	First Affiliated Hospital Xi'an Jiaotong University|Eureka Therapeutics Inc.|Aeon Therapeutics (Shanghai) Co., Ltd.	All	18 Years to 75 Years   (Adult, Older Adult)	Early Phase 1	27	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XJTU1AF2017LSL-C002	December 6, 2017	December 6, 2019	January 6, 2020	March 25, 2019		March 27, 2019	The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China		https://ClinicalTrials.gov/show/NCT03888859
74	NCT01868087	Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study		Completed	No Results Available	Bladder Cancer|Radical Cystectomy|Urinary Bladder Neoplasms|Surgery	Dietary Supplement: Boost Plus®|Dietary Supplement: Impact Advanced Recovery®	Immune and Inflammation Response|preservation of body weight and fat free mass (FFM)|count of infections after surgery|hospital readmission rate	Jill Hamilton-Reeves, PhD RD LD|American Cancer Society, Inc.|Nestlé|University of Kansas Medical Center	Male	40 Years to 90 Years   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	13730	July 2013	March 2016	March 2016	June 4, 2013		April 7, 2016	University of Kansas Medical Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT01868087
75	NCT03980249	Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells		Not yet recruiting	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: Carvedilol	Survival curve of overall survival|Survival curve of progression free survival|Quantify Circulating Tumor Cells (CTCs)	West Virginia University|NovoCure Ltd.|West Virginia Clinical and Translational Science Institute	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	WVU020318	September 2019	December 2021	June 2022	June 10, 2019		July 31, 2019	WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States	"Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/49/NCT03980249/ICF_000.pdf	https://ClinicalTrials.gov/show/NCT03980249
76	NCT00884520	An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037	VM4-037	Completed	No Results Available	Lung Cancer|Squamous Cell Carcinoma|Head and Neck Cancer|Hepatic Carcinoma|Renal Cell Carcinoma	Drug: [F-18] VM4-037	Safety will be the outcome demonstrated in this clinical trial through analyses of adverse events in subjects who receive study drug.	Siemens Molecular Imaging	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	16	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)	DVM4000	April 2009	March 2010	March 2010	April 20, 2009		March 16, 2010	Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00884520
77	NCT03059940	Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer		Recruiting	No Results Available	Smoking Cessation	Behavioral: Questionnaires|Procedure: Low Dose Computed Tomography Scan|Other: Shared Decision Making + Video|Behavioral: Cessation Counseling|Behavioral: Quitline|Behavioral: Pharmacotherapy Discussion|Drug: Nicotine Patch|Drug: Anti-Smoking Drug|Behavioral: Tobacco Treatment Program|Other: Carbon Monoxide (CO) Level Test	Smoking Abstinence Rate	M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Pfizer	All	50 Years and older   (Adult, Older Adult)	Early Phase 1	1260	Other|NIH|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention	2016-0626|R01-CA 2027078-01|NCI-2018-01219	June 16, 2017	June 2022	June 2023	February 23, 2017		July 16, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03059940
78	NCT01748149	Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas		Active, not recruiting	No Results Available	Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas	Drug: Vemurafenib	Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D)|Toxicity Profile (dose limiting toxicities)|Concentrations of vemurafenib in the blood found through pharmacokinetic (PK) samples|Objective Response|Intra-tumoral drug concentration Comparison|Progression-free survival	University of California, San Francisco|Genentech, Inc.	All	up to 25 Years   (Child, Adult)	Early Phase 1	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC #120819|NCI-2014-00387	February 2014	January 2020	June 2020	December 12, 2012		March 5, 2019	Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Mount Zion, San Francisco, California, United States|UCSF Medical Center-Parnassus, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota/Masonic Children's Hospital, Minneapolis, Minnesota, United States|Saint Louis Children's Hospital, Saint Louis, Missouri, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Texas Children's Hospital, Houston, Texas, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01748149
79	NCT03131934	Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant	ITREC	Recruiting	No Results Available	Post-transplant Lymphoproliferative Disease|Transplant-Related Hematologic Malignancy	Biological: Autologous EBV-CTL transduced with vector SFG-CNA12|Biological: Autologous EBV-CTL transduced with control vector SFG-CNA8|Procedure: Leucapheresis	Toxicity at 6 weeks post infusion|Persistence and frequency of circulating EBV CTL|Disease response|Relapse rate|Disease free survival|Organ graft Rejection	University College, London|bluebird bio	All	1 Year to 70 Years   (Child, Adult, Older Adult)	Early Phase 1	18	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	UCL/16/0529	May 31, 2019	June 30, 2020	May 15, 2025	April 27, 2017		June 13, 2019	Great Ormond Street Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03131934
80	NCT02872025	Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)		Recruiting	No Results Available	Carcinoma, Intraductal, Noninfiltrating	Drug: Pembrolizumab	Maximum tolerated dose (MTD)|Dose-limiting toxicities (DLTs)|Percentage of patients who demonstrate an increase (baseline vs. post intralesional injection) in intralesional CD8+ T cells (treated vs. untreated participants) as measured using multiplex immunofluorescence on FFPE tissue sections	Laura Esserman|Merck Sharp & Dohme Corp.|University of California, San Francisco	Female	18 Years and older   (Adult, Older Adult)	Early Phase 1	48	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16704	December 12, 2016	March 2019	September 2019	August 18, 2016		June 21, 2018	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT02872025
81	NCT03943472	BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma		Not yet recruiting	No Results Available	Multiple Myeloma	Biological: Anti-BCMA CAR-T cells|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Immune inhibitors	Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 5.0|Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm|Duration of CAR-positive T cells in circulation	Hrain Biotechnology Co., Ltd.|Shanghai Changzheng Hospital	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	10	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment	anti-BCMA CART	July 2019	November 2021	May 2022	May 9, 2019		June 24, 2019	Shanghai Changzheng Hospital, Shanghai, Shanghai, China		https://ClinicalTrials.gov/show/NCT03943472
82	NCT03661554	BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma	BCMA CAR-T	Recruiting	No Results Available	Relapsed and Refractory Multiple Myeloma	Biological: BCMA CAR-T Cells	Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	The Pregene (ShenZhen) Biotechnology Company, Ltd.|Henan Cancer Hospital	All	18 Years to 75 Years   (Adult, Older Adult)	Early Phase 1	15	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PRG 1801	April 10, 2018	October 30, 2018	November 30, 2018	September 7, 2018		September 7, 2018	Pregene Shenzhen Biotechnology Co., Ltd., Shenzhen, Guangdong, China		https://ClinicalTrials.gov/show/NCT03661554
83	NCT03559764	Study of BCMA CAR-T in Multiple Myeloma		Not yet recruiting	No Results Available	Relapsed and Refractory Multiple Myeloma	Biological: Anti-BCMA CAR T cells	The safety of CAR T is evaluated to determine if CRS occurred	Allife Medical Science and Technology Co., Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	20	Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BCMA CAR T-HNRM-01	June 2018	February 2020	May 2020	June 18, 2018		June 18, 2018			https://ClinicalTrials.gov/show/NCT03559764
84	NCT03812562	Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection		Recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Nivolumab|Radiation: Yttrium Y 90 Glass Microspheres	Recurrence rate|Incidence of adverse events|Overall survival (OS)|Overall increase in future liver remnant (FLR)	Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	12	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 18I03|NCI-2018-03602|P30CA060553	February 7, 2019	June 1, 2021	June 1, 2022	January 23, 2019		February 20, 2019	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03812562
85	NCT02546752	Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine		Completed	No Results Available	Human Papilloma Virus Infection Type 11|Human Papilloma Virus Infection Type 16|Human Papilloma Virus Infection Type 18|Human Papilloma Virus Infection Type 6|Cervical Cancer	Other: THEO	Outcome Measure 1: Difference Between Average HPV Vaccine Series Initiation and Completion Rates|Outcome Measure 1: Relative Difference in Time of Appointment	Regenstrief Institute, Inc.|Merck Sharp & Dohme Corp.	All	11 Years to 17 Years   (Child)	Early Phase 1	1306	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Health Services Research	Merck - 20	September 2015	May 2016	May 2016	September 11, 2015		May 25, 2016	Eskenazi Health Outpatient Care Center, Indianapolis, Indiana, United States|Eskenazi Health Center Blackburn, Indianapolis, Indiana, United States|Eskenazi Health Center Forest Manor, Indianapolis, Indiana, United States|Eskenazi Health West 38th Street, Indianapolis, Indiana, United States|Eskenazi Health Pecar, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT02546752
86	NCT01861340	Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma		Completed	No Results Available	Myeloma	Drug: Lenalidomide, Dexamethasone, and MEDI-551	The effect of Lenalidomide, dexamethasone and Medi-551 on multiple myeloma cancer stem cells (CSCs).|The safety of Medi-551 when combined with Lenalidomide and dexamethasone.	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|MedImmune LLC	All	18 Years to 100 Years   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	J1340|NA_00081182	May 2014	April 2016	July 2016	May 23, 2013		September 10, 2018	The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT01861340
87	NCT03371420	PET Imaging of Subjects Using 124I-PU-AD		Completed	No Results Available	Lymphoma|Solid Malignancy|Alzheimer Disease|Myeloma	Drug: PU-AD|Device: PET Scan|Other: Blood Draws	Pharmacokinetic profile of 124I-PU-AD: area under the curve (AUC)|Pharmacokinetic profile of 124I-PU-AD: maximum plasma concentration (Cmax)|Pharmacokinetic profile of 124I-PU-AD: trough plasma concentration (Cmin)|Pharmacokinetic profile of 124I-PU-AD: plasma half-life (T1/2)|Pharmacokinetic profile of 124I-PU-AD: time to maximum plasma concentration (Tmax)|Incidence of adverse events	Samus Therapeutics, Inc.|Memorial Sloan Kettering Cancer Center|Weill Medical College of Cornell University|Rockefeller University	All	21 Years to 90 Years   (Adult, Older Adult)	Early Phase 1	5	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	PU-AD-00-001	April 2016	June 10, 2019	June 10, 2019	December 13, 2017		June 11, 2019	Memorial Sloan Kettering, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03371420
88	NCT00743353	Exploratory, Phase 0 Study of Positron Emission Tomography (PET) Imaging Agent, F-18 RGD-K5	K5	Completed	No Results Available	Sarcoma|Melanoma|Lung Cancer|Breast Cancer|High Grade Gliomas	Drug: F-18 RGD-K5	To collect bio-distribution data to calculate dosimetry values in normals and obtain and evaluate PET images in cancer subjects for resolution of [F-18]RGD-K5	Siemens Molecular Imaging	All	Child, Adult, Older Adult	Early Phase 1	16	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	K5-100	August 2008	January 2009	January 2009	August 28, 2008		February 2, 2009	Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00743353
89	NCT03316274	Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma		Recruiting	No Results Available	Kaposi Sarcoma|HIV/AIDS|Immunosuppression	Drug: Intra-lesional injection of nivolumab	Safety and tolerability as assessed by Common Terminology Criteria for Adverse Events version 4 (CTCAE v. 4)|The changes in frequency of circulating activated T cells in the skin KS lesions as determined by immunohistochemistry and flow cytometry|The changes in number of circulating activated T cells in the skin KS lesions as determined by immunohistochemistry and flow cytometry|The changes in frequency of circulating activated T cells in the peripheral blood as determined by flow cytometry|The changes in number of circulating activated T cells in the peripheral blood as determined by flow cytometry|The changes in PD-1 expression as determined by immunohistochemistry in lesions|The changes in PD-L1 expression as determined by immunohistochemistry in lesions	University of California, San Francisco|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	12	Other|Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC17872	April 15, 2018	December 2019	June 2021	October 20, 2017		April 5, 2019	Zuckerberg San Francisco General Hospital, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03316274
90	NCT03224819	Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia		Recruiting	No Results Available	Acute Myeloid Leukemia	Drug: AMG 673	Subject incidence and grade of adverse events|Dose limiting toxicities (DLTs)|Pharmacokinetic parameter - half-life|Pharmacokinetic parameter - steady state|Pharmacokinetic parameter - Concentration|Pharmacokinetic parameter - Volume of distribution|Pharmacokinetic parameter - Clearance of AMG 673	Amgen	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	50	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	20160377	September 7, 2017	March 22, 2020	March 22, 2020	July 21, 2017		December 27, 2018	Research Site, Birmingham, Alabama, United States|Research Site, Duarte, California, United States|Research Site, Houston, Texas, United States|Research Site, Seattle, Washington, United States|Research Site, Melbourne, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, München, Germany		https://ClinicalTrials.gov/show/NCT03224819
91	NCT01843634	Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia		Completed	No Results Available	Acute Myeloid Leukemia	Drug: ODSH	Safety by incidence of serious events|Efficacy by time to platelet recovery	Cantex Pharmaceuticals	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	10	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	IRB 63137	August 2013	April 2015	April 2015	April 30, 2013		March 23, 2016	Huntsman Cancer Institute, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01843634
92	NCT03893487	Fimepinostat in Treating Brain Tumors in Children and Young Adults	PNOC016	Recruiting	No Results Available	Diffuse Intrinsic Pontine Glioma|Recurrent Anaplastic Astrocytoma|Recurrent Glioblastoma|Recurrent Malignant Glioma|Recurrent Medulloblastoma	Drug: Fimepinostat|Procedure: Therapeutic Conventional Surgery	Penetration of fimepinostat across the blood brain barrier (BBB)	Sabine Mueller, MD, PhD|Pacific Pediatric Neuro-Oncology Consortium|Cannonball Kids' Cancer Foundation|Curis, Inc.|University of California, San Francisco	All	3 Years to 39 Years   (Child, Adult)	Early Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	18086|PNOC016	August 7, 2019	June 2022	June 2027	March 28, 2019		August 12, 2019	University of California, San Francisco, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT03893487
93	NCT00898768	Capsule Endoscopy to Screen for Small Bowel Neoplasia in Lynch Syndrome	CELSIUS	Completed	No Results Available	Lynch Syndrome|Small Bowel Neoplasia	Procedure: Capsule endoscopy	The main outcome measure will be the number of neoplastic small bowel lesions, with determination of size, location and histological characteristics at baseline and at follow-up after 2 years.|The secondary endpoint will be the number of complications following endoscopic procedures: rates of capsule retention and postpolypectomy bleeding and perforation.	University Medical Center Groningen|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|Erasmus Medical Center|Leiden University Medical Center|St. Antonius Hospital|The Netherlands Cancer Institute|University Medical Center Nijmegen|Maastricht University Medical Center|Free University Medical Center|Medtronic - MITG	All	35 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	200	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening	CELSIUS|Dutch Cancer Society 2008-4187	May 2009	December 2014	December 2014	May 12, 2009		December 9, 2014	University Medical Center Groningen, Groningen, Netherlands		https://ClinicalTrials.gov/show/NCT00898768
94	NCT01174940	Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease		Completed	No Results Available	Stem Cell Leukemia of Unclear Lineage|Graft Versus Host Disease	Drug: extracorporeal photopheresis	Presence/absence of grade II-IV acute Graft versus Host Disease (aGVHD)|proportion of patients who develop chronic Graft versus Host Disease (cGVHD) and experience relapse of primary disease.	University of Kansas Medical Center|Mallinckrodt	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	22	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12047	June 2010	August 2014	August 2015	August 4, 2010		January 9, 2017	University of Kansas Medical Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT01174940
95	NCT01557686	Health Counseling and Exercise in Patients With Acute Leukemia - Pilot Study	PACE-AL	Completed	No Results Available	Acute Leukemia	Behavioral: Health counseling and exercise	Feasibility - adherence rates|Adverse events|6MWD|Attrition|Timed chair stand|Timed bicep curl|FACT-Anemia|HADS|SF36|MDSAI	Universitetshospitalernes Center for Sygepleje|Novo Nordisk A/S|Lundbeck Foundation	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	H-4-2010-046 Pilot	May 2010	February 2011	February 2011	March 19, 2012		March 19, 2012	Copenhagen University Hospital, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark		https://ClinicalTrials.gov/show/NCT01557686
96	NCT03996252	Combination Topical Therapy for Treatment of Scalp Actinic Keratoses		Not yet recruiting	No Results Available	Actinic Keratoses	Drug: Calcipotriene 0.005% Foam|Drug: Efudex 5% Topical Cream	Percentage of change in the number of scalp actinic keratoses from baseline|Complete and partial (>75%) clearance of actinic keratoses|Composite score of erythema, itching and skin pain after topical of calcipotriene 0.005% foam and 5-fluorouracil 5% cream application for four consecutive nights to scalp actinic keratoses.	Tulane University|Mayne Pharma International Pty Ltd	All	40 Years and older   (Adult, Older Adult)	Early Phase 1	15	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	052090	July 1, 2019	January 1, 2020	June 8, 2020	June 24, 2019		June 24, 2019			https://ClinicalTrials.gov/show/NCT03996252
97	NCT02507232	Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas		Recruiting	No Results Available	Glioma	Device: NovoTTF-200A|Drug: Temozolomide	Toxicity associated with treatment with NovoTTF-200A alone and combined with temozolomide|Efficacy of NovoTTF-200A alone and combined with temozolomide|12-month objective response rate (ORR) of NovoTTF-200A alone and combined with temozolomide|Effects of NovoTTF-200A alone and combined with temozolomide on seizure activity|Effects of NovoTTF-200A alone and combined with temozolomide on quality of life (QOL)|Frequency of transformation from low-grade glioma into high-grade glioma	Santosh Kesari|NovoCure Ltd.|John Wayne Cancer Institute	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	22	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	JWCI-16-1101	April 17, 2017	April 2021	April 2022	July 23, 2015		May 20, 2019	John Wayne Cancer Institute, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT02507232
98	NCT01425749	Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI	Mel55	Completed	Has Results	Melanoma	Biological: recMAGE-A3 + AS15 ASCI	Number of Participants With Treatment-related Adverse Events as a Measure of Safety and Tolerability|Enumeration of CD4 and CD8 T Cell Responses to MAGE-A3 Epitopes in the Injection Site-draining Lymph Node (Sentinel Immunized Node, SIN) as a Measure of Immunogenicity.|Enumeration of CD4+ and CD8+ T Cells Reactive to MAGE-A3 Epitopes in Peripheral Blood as a Measure of Immunogenicity.|Identification of Antibody Responses to MAGE-A3 After MAGE-A3 ASCI Administration as a Measure of Immunogenicity.|Characterization of the Maturation and Activation of Dendritic Cell (DC) Populations in the Sentinel Immunized Node (SIN) After Treatment With MAGE-A3 ASCI.|A Preliminary Evaluation of Cellular Components of the Injection Site Microenvironment for Cutaneous Immunization With MAGE-A3 ASCI (Activated T Cells, Th1,Th2, Th17 Infiltrating CD4 Cells, Regulatory T Cells, and Myeloid-derived Suppressor Cells).	Craig L Slingluff, Jr|GlaxoSmithKline|University of Virginia	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	25	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CSlingluff	June 2011	July 2013	October 2015	August 30, 2011	April 4, 2016	April 4, 2016	University of Virginia, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT01425749
99	NCT03975205	To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames	Doxil	Not yet recruiting	No Results Available	Lymphoma Leukemia	Drug: Doxorubicin	Bioavailability of Doxil versus Doxorubicin	Sutphin Drugs|Bharath Charitable Cancer Hospital and Institute	All	18 Years to 75 Years   (Adult, Older Adult)	Early Phase 1	500	Industry|Other	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Global CRO Doxil	July 1, 2019	October 31, 2019	December 31, 2019	June 5, 2019		June 5, 2019	Bharat Cancer Hospital, Surat, Gujarat, India		https://ClinicalTrials.gov/show/NCT03975205
100	NCT03910842	Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy		Recruiting	No Results Available	Non-Hodgkin Lymphoma of Intestine|Leukemia	Biological: CD19-TriCAR-T/SILK	safty (Incidence of treatment-related adverse events as assessed by CTCAE v4.03)|Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)	Timmune Biotech Inc.|Hunan Provincial People's Hospital	All	up to 18 Years   (Child, Adult)	Early Phase 1	12	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	T2018-14	May 15, 2019	April 15, 2022	October 15, 2022	April 10, 2019		May 1, 2019	Hunan Provincial People's Hospital, Changsha, Hunan, China		https://ClinicalTrials.gov/show/NCT03910842
101	NCT03790891	Treatment of Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy		Recruiting	No Results Available	Non-Hodgkin Lymphoma	Biological: CD19-TriCAR-T/SILK	safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）|Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)|Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria）|Duration of Response （The time from response to relapse or progression）|Progression Free Survival （The time from the first day of treatment to the date on which disease progresses）|Overall Survival （The number of patient alive, with or without signs of cancer）	Timmune Biotech Inc.	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	12	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2018-127	January 5, 2019	June 1, 2021	January 1, 2022	January 1, 2019		March 29, 2019	Hainan General Hospital, Haikou, Hainan, China		https://ClinicalTrials.gov/show/NCT03790891
102	NCT03893019	MB-CART20.1 Melanoma		Recruiting	No Results Available	Melanoma (Skin)	Biological: MB-CART20.1	Determination of MTD|Safety and Toxicity Assessment per Adverse Event reporting classified according to CTCAE V5.0|Clinical Response|Frequency of B-cell aplasia|Phenotype and Persistence of infused MB-CART20.1|Presence and phenotype of MB-CART20.1 and B cells in biopsies|Number of CD20+ tumor cells|Persistence of T-cell expansion for each dose group	Miltenyi Biotec GmbH|DLR German Aerospace Center	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	15	Industry|Other	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M-2015-307	March 8, 2019	July 2021	July 2021	March 27, 2019		March 27, 2019	University Hospital of Cologne - Clinic for Internal Medicine I, Cologne, NRW, Germany		https://ClinicalTrials.gov/show/NCT03893019
103	NCT03649529	Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy		Recruiting	No Results Available	Malignant Melanoma	Biological: GPA-TriMAR-T	safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）|Complete response rate[CR] （Complete response rate per the revised International Working Group (IWG) Response Criteria）|Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria）|Duration of Response （The time from response to relapse or progression）|Progression Free Survival （The time from the first day of treatment to the date on which disease progresses.）|Overall Survival （The number of patient alive, with or without signs of cancer）	Timmune Biotech Inc.|The Second Affiliated Hospital of Hainan Medical University|Hainan Cancer Hospital	All	18 Years to 69 Years   (Adult, Older Adult)	Early Phase 1	6	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	T2018-7	September 27, 2018	September 15, 2021	January 1, 2022	August 28, 2018		April 1, 2019	Hainan Cancer Hospital, Haikou, Hainan, China|The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China		https://ClinicalTrials.gov/show/NCT03649529
104	NCT01298310	A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)		Completed	No Results Available	Morton's Neuroma	Drug: Xylocaine|Drug: Placebo	The baseline phenotypic Quantitative sensory testing (QST) variables (e.g. heat, cold, touch and mechanical pain perception). Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)|The effect of Xylocaine compared to placebo in QST variables. Sensory tests will be performed to measure pain and skin sensitivity by use of different pressure (mN) and temperature ( C)|Frequency/severity of adverse events	AstraZeneca	All	18 Years to 80 Years   (Adult, Older Adult)	Early Phase 1	27	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science	D2285M00032|Eudract no: 2010-024295-26	February 2011	May 2012	May 2012	February 17, 2011		May 22, 2012	Research Site, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT01298310
105	NCT02517502	Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy		Active, not recruiting	No Results Available	Cognitive Dysfunction	Drug: DHA|Drug: Placebo	Number of potentially eligible subjects who consent to participate in the study.|Number of enrolled subjects who complete all cognitive assessments at all three defined timepoints.|Number of enrolled subjects who take at least 70% of prescribed study agent.|Number of subjects reporting serious adverse events|Change in Cognitive Ability-General Concerns Questionnaire|Change in Cognitive Ability-Abilities Questionnaire|Change in Quality of Life Questionnaire|Level of Physical Activity Questionnaire|Change in Cognitive Function test|Measurement of Cognitive Function Mobile Cognitive Assessment Battery (MCAB) Questionnaire	Carol Fabian, MD|DSM Nutritional Products, Inc.|University of Kansas Medical Center	Female	18 Years to 65 Years   (Adult, Older Adult)	Early Phase 1	24	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care	STUDY00002415	July 2015	June 2019	June 2019	August 7, 2015		February 6, 2019	Decatur Memorial Hospital, Decatur, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT02517502
106	NCT01171092	A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma		Completed	No Results Available	Malignant Lymphoma, Stem Cell Type|Autologous Transplant	Drug: bortezomib and G-CSF	Determine the effectiveness of the combination of bortezomib and G-CSF|Assess the safety of the combination of bortezomib and G-CSF	University of Kansas Medical Center|Millennium Pharmaceuticals, Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	21	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11803|X05279	September 2010	January 2013	December 2014	July 28, 2010		January 11, 2017	University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kansas Medical Center, Westwood Campus, Westwood, Kansas, United States		https://ClinicalTrials.gov/show/NCT01171092
107	NCT01022021	Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine		Completed	No Results Available	Lymphoma	Drug: Rituximab|Drug: Bendamustine	To assess the efficacy of G-CSF induced PBSC mobilization after two cycles of rituximab and Bendamustine (BR) as salvage therapy in patients with relapsed non-Hodgkins lymphoma	University of Kansas Medical Center|Cephalon	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	17	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	11908	January 2010	April 2014	August 2015	December 1, 2009		January 10, 2017	University of Kansas Medical Center, Kansas City, Kansas, United States		https://ClinicalTrials.gov/show/NCT01022021
108	NCT04028245	A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma	SPARC-1	Recruiting	No Results Available	Carcinoma, Renal Cell	Drug: Spartalizumab|Drug: Canakinumab	Percentage of subjects who proceed to radical nephrectomy|Quantification of CD8 T cell infiltration into the tumor / peritumoral area infiltrates|Quantification of immune cell populations (PMN-MDSC) in the tumor/ peritumoral area|Objective tumor response rate	Charles G. Drake|Novartis|Columbia University	All	18 Years to 99 Years   (Adult, Older Adult)	Early Phase 1	14	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAS2814	August 2019	December 2020	December 2021	July 22, 2019		July 23, 2019	Columbia University Medical Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT04028245
109	NCT02591654	MRI and PET to Assess Pembrolizumab Response	MPAK	Active, not recruiting	No Results Available	Malignant Melanoma, Metastatic	Drug: Pembrolizumab|Drug: FLT PET	Prevalence of lesion detection (sensitivity)|Difference in lesion metrics|Change in patient response (immunoscore)|Change in patient response (expression levels)|Change in RECIST Index	Yvonne Saenger|Merck Sharp & Dohme Corp.|Columbia University	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	6	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AAAO2558	October 2015	November 2022	November 2024	October 29, 2015		April 5, 2019	Columbia University, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02591654
110	NCT02278510	Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma		Completed	No Results Available	Malignant Glioma|WHO Grade III or IV Recurrent Glioma	Drug: Topotecan|Drug: Gadolinium DTPA|Device: Cleveland Multiport Catheter	Spatial distribution of topotecan|Number of catheter- and/or drug-related complications|Objective response rate of subjects given topotecan|Median progression-free survival of HGG subjects given topotecan|Median overall survival of HGG subjects given topotecan|Proportion of progression free HGG subjects given topotecan	Michael Vogelbaum, MD, PhD|Infuseon Therapeutics, Inc.|Case Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	3	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	INFT1314|NCI-2014-02248	December 9, 2014	November 10, 2015	November 10, 2015	October 30, 2014		March 31, 2017	Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT02278510
111	NCT03995706	Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0		Recruiting	No Results Available	Glioblastoma	Drug: Sacituzumab Govitecan	Ratio of SN-38 and its metabolites relative to serum concentration	The University of Texas Health Science Center at San Antonio|Immunomedics, Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CTMS# 19-0069|HSC20190378H	July 17, 2019	July 10, 2021	July 10, 2022	June 24, 2019		August 1, 2019	Mays Cancer Center, UT Health San Antonio, San Antonio, Texas, United States		https://ClinicalTrials.gov/show/NCT03995706
112	NCT03238365	Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck		Active, not recruiting	No Results Available	Lip, Oral Cavity and Pharynx|Larynx	Biological: Nivolumab|Drug: Tadalafil|Procedure: Therapeutic Conventional Surgery	Change in immune cell polarization (Th1/Th2; M1/M2) in peripheral blood and tumor specimens using multiplex cytokine analysis|Prevalence of intratumoral immune cell populations	Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.210	August 10, 2017	December 16, 2019	December 16, 2020	August 3, 2017		July 12, 2019	Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Vanderbilt University, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03238365
113	NCT02630030	Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma		Completed	No Results Available	Glioblastoma	Drug: Ixazomib	Concentration of ixazomib in tumor tissue|Concentration of ixazomib in blood and plasma samples|Incidence of adverse events after single dose administration of ixazomib, assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03	Emory University|Takeda	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	3	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	IRB00083003|NCI-2015-01682|X16071|Winship3017-15	March 2016	July 2018	July 2018	December 15, 2015		August 15, 2018	Emory University/Winship Cancer Institute, Atlanta, Georgia, United States		https://ClinicalTrials.gov/show/NCT02630030
114	NCT01275586	Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas		Completed	Has Results	Neurofibromatosis|NF1|Neurofibromas	Drug: Tasigna	Disease Response	Indiana University|Novartis	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	6	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	1008-06|CAMN107YUS29T	January 2011	July 2016	October 2016	January 12, 2011	April 12, 2017	April 12, 2017	Riley Hospital for Children, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT01275586
115	NCT00972933	Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma		Completed	No Results Available	Melanoma	Drug: ipilimumab	To study the effects of ipilimumab upon the host immune response in nodal metastatic melanoma and in the peripheral blood comparing pre-treatment with post-treatment (baseline, 6 weeks) immunologic features.|To study the effects of ipilimumab upon the host immune response.|To collect pilot data comparing pre-treatment with post-treatment proteomic and genetic features.|To evaluate the clinical efficacy of preoperative neoadjuvant therapy with ipilimumab in high risk clinically and pathologically node-positive melanoma patients (AJCC stage IIIB-C).|To collect safety data and evaluate the safety of neoadjuvant therapy with ipilimumab in high risk clinically and pathologically node-positive melanoma patients (AJCC stage IIIB-C).	Diwakar Davar|Bristol-Myers Squibb|University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	59	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08-144	December 2009	July 17, 2013	September 26, 2017	September 9, 2009		December 7, 2017	University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00972933
116	NCT00890786	A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas		Completed	No Results Available	Newly Diagnosed High-Grade Gliomas|Diffuse Intrinsic Pontine Glioma	Drug: Temozolomide|Drug: Bevacizumab|Drug: Irinotecan	To determine the toxicities and feasibility of the proposed treatment regimen in patients with high-grade glioma and diffuse intrinsic brainstem glioma|To determine 1-year EFS, median PFS and median OS in newly diagnosed patients with high-grade glioma treated with radiotherapy and concurrent temozolomide, bevacizumab followed by bevacizumab, irinotecan and temozolomide for 12 courses|To determine the 1-year EFS, median PFS and median OS in newly diagnosed patients with diffuse intrinsic brainstem glioma treated with radiotherapy and concurrent bevacizumab followed by bevacizumab and irinotecan for 12 courses|To estimate blood levels of VEGF in circulating endothelial cells in patients at different time points|To document changes in MR perfusion and diffusion within 24-48 hours after the 2nd dose of bevacizumab during radiotherapy|To correlate functional changes in tumor with responses to treatment using MR diffusion/perfusion imaging|To correlate the results of the biology studies in serum or tumor with PFS|To conduct gene expression profiling, CGH and SNP arrays in patients with high-grade gliomas|To assess telomerase activity, hTert expression, and telomere length in patients with high-grade gliomas|To assess the health-related quality of life of patients by parent report, and when possible, patient report at key points in therapy|To assess functional abilities and level of independence of patients during and following treatment	Children's Hospital Medical Center, Cincinnati|Genentech, Inc.	All	3 Years to 30 Years   (Child, Adult)	Early Phase 1	27	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HGG	May 2009	October 2014	December 2017	April 30, 2009		May 2, 2018	Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States		https://ClinicalTrials.gov/show/NCT00890786
117	NCT00795457	Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas		Completed	No Results Available	Astrocytoma|Oligo-Astrocytoma|Glioma	Biological: GAA/TT-peptide vaccine and poly-ICLC	Induction of GAA-specific T-cell response|The incidence and severity of adverse events associated with the vaccine regime will be assessed, with an early stopping rule based on the frequency of Regimen Limiting Toxicity (RLT).|Clinical Response: Radiological response will be determined using the standard WHO response criteria. Based on serial magnetic resonance imaging (MRI) scans 2-year progression-free survival (PFS) will be evaluated in an exploratory manner.|Biopsy/resection will be encouraged for patients who develop progression. Whenever post-vaccine tumor tissues are available, they will be analyzed for GAA expression status and infiltration of GAA-specific T-cells.|Influence of RT on induction of GAA-specific immune response: we will compare the rate and magnitude of GAA-specific immune responses in Cohorts 1 and Cohort 2 using IFN-gamma-enzyme-linked immuno-spot (ELISPOT), and tetramer assays.	Ian F. Pollack, M.D.|Oncovir, Inc.|University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	13	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	07-057|R21CA133859-01A1	January 2009	February 2013	July 2015	November 21, 2008		July 6, 2017	Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00795457
118	NCT01091792	Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)		Completed	No Results Available	Glioblastoma Multiforme	Drug: Bevacizumab	Changes in the peripheral blood T-reg profile between pretreatment and 4 weeks after completion of treatment with the addition of bevacizumab to RT and TMZ in patients with glioblastoma|Immunologic shift in the phenotypic T cell, B cell, NK cell and DC repertoire induced by RT-TMZ-BEV comparing pretreatment and 4 weeks after completion of treatment	Dartmouth-Hitchcock Medical Center|Genentech, Inc.	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	13	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	D0947	March 2010	April 2, 2015	April 2, 2015	March 24, 2010		May 25, 2018	Dartmouth Hithcock Medcial Center, Lebanon, New Hampshire, United States		https://ClinicalTrials.gov/show/NCT01091792
119	NCT04034446	CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)		Not yet recruiting	No Results Available	Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia	Biological: CD19-CD22 CAR-T cells	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Overall remission rate (ORR)|Response at Day 28 days|Percentage of patients who achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at month 6 without SCT between CD19-CD22 CAR-T cells infusion and Month 6 response assessment.|Percentage of patients who achieve CR or CRi with minimal residual disease (MRD) negative bone marrow|Relapse-free survival (RFS)|Duration of remission (DOR)|Overall survival (OS)	Institute of Hematology & Blood Diseases Hospital|Juventas Cell Therapy Ltd.	All	3 Years and older   (Child, Adult, Older Adult)	Early Phase 1	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HY004001	August 2019	January 2020	December 2021	July 26, 2019		July 26, 2019	Institute of Hematology & Blood Diseases Hospital, Tianjin, China		https://ClinicalTrials.gov/show/NCT04034446
120	NCT03824964	Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma		Not yet recruiting	No Results Available	Refractory B-Cell Lymphoma	Biological: Anti-CD19/CD22 CAR NK Cells	Occurrence of treatment related adverse events as assessed by CTCAE v4.0	Allife Medical Science and Technology Co., Ltd.|Beijing Cancer Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	10	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CD19/CD22 CAR NK-BJZL-01	February 1, 2019	January 1, 2020	January 1, 2021	January 31, 2019		January 31, 2019			https://ClinicalTrials.gov/show/NCT03824964
121	NCT03824951	Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma		Not yet recruiting	No Results Available	Refractory B-Cell Lymphoma	Biological: Anti-CD19 iCAR NK Cells	Occurrence of treatment related adverse events as assessed by CTCAE v4.0	Allife Medical Science and Technology Co., Ltd.|Beijing Cancer Hospital	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	10	Industry|Other	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CD19 iCAR NK-BJZL-01	February 1, 2019	January 1, 2020	January 1, 2021	January 31, 2019		January 31, 2019			https://ClinicalTrials.gov/show/NCT03824951
122	NCT03692767	Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma		Not yet recruiting	No Results Available	Refractory B-Cell Lymphoma	Biological: Anti-CD22 CAR NK Cells	Occurrence of treatment related adverse events as assessed by CTCAE v4.0	Allife Medical Science and Technology Co., Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	9	Industry	Interventional	Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CD22 CAR NK-BJZL-01	March 2019	November 2020	November 2021	October 2, 2018		January 30, 2019			https://ClinicalTrials.gov/show/NCT03692767
123	NCT03690310	Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma		Not yet recruiting	No Results Available	Refractory B-Cell Lymphoma	Biological: Anti-CD19 CAR NK Cells	Occurrence of treatment related adverse events as assessed by CTCAE v4.0	Allife Medical Science and Technology Co., Ltd.	All	18 Years to 70 Years   (Adult, Older Adult)	Early Phase 1	9	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CD19 CAR NK-BJZL-01	March 2019	November 2020	November 2021	October 1, 2018		January 31, 2019			https://ClinicalTrials.gov/show/NCT03690310
124	NCT03895944	ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma		Recruiting	No Results Available	CD19+ Lymphoma, B-Cell|CD19+ Leukemia, B-Cell	Biological: ET190L1-ARTEMIS™ T cells -iv low dose|Biological: ET190L1-ARTEMIS™ T cells -iv middle dose|Biological: ET190L1-ARTEMIS™ T cells - iv high dose	Frequency of ARTEMIS T cell treatment-related adverse events|Number of ET190L1-ARTEMIS™ T cells in peripheral blood|% of ET190L1-ARTEMIS™ T cells in peripheral blood|Maximum Tolerated Dose|Tmax of serum cytokine levels|Time to baseline for serum cytokine levels|AUC of serum cytokine levels|Rate of disease response|Progression free survival (PFS)|Median Survival（MS）|Overall Survival（OS）|B cell depletion (Number)|B cell depletion (%)	First Affiliated Hospital Xi'an Jiaotong University|Eureka Therapeutics Inc.	All	18 Years to 75 Years   (Adult, Older Adult)	Early Phase 1	18	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	XJTU1AF2017LSL-C001	December 6, 2017	December 6, 2019	December 6, 2019	March 29, 2019		March 29, 2019	First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China		https://ClinicalTrials.gov/show/NCT03895944
125	NCT03244176	Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study	AvR-CHOP	Recruiting	No Results Available	Lymphomas Non-Hodgkin's B-Cell	Drug: Avelumab	Immune-related toxicity|Response Rate|Failure Free Survival|Overall Survival|Overall Toxicity of Treatment	Austin Health|Merck KGaA, Darmstadt, Germany	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	28	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MS100070-0068	July 21, 2017	February 2021	July 2025	August 9, 2017		January 15, 2019	Ballarat Health, Ballarat, Victoria, Australia|Eastern Health, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia		https://ClinicalTrials.gov/show/NCT03244176
126	NCT01913119	A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma	Ro-ENKTL	Completed	No Results Available	Histologically Proven Extranodal NKTcell Lymphoma	Drug: Romidepsin	Rate of overall disease control including CR, PR, and SD|Number of participants with adverse events|Time to progression|overall survival	Samsung Medical Center|Celgene Corporation	All	20 Years to 79 Years   (Adult, Older Adult)	Early Phase 1	16	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2012-10-059	July 2013	July 2013	July 2013	July 31, 2013		July 31, 2013	National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Korea Cancer Center Hospital, Nowon-gu, Seoul, Korea, Republic of|Severance Hospital, Seodaemun-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of		https://ClinicalTrials.gov/show/NCT01913119
127	NCT03099564	Pembrolizumab Plus Y90 Radioembolization in HCC Subjects		Recruiting	No Results Available	Hepatocellular Carcinoma	Drug: Pembrolizumab|Device: Y90 radioembolization	Progression free survival (PFS)|Assess Safety - toxicities as defined by the NCI CTCAE v4|Time to progression (TTP)|Objective response rate (ORR)|Estimate overall survival (OS)	Autumn McRee, MD|Merck Sharp & Dohme Corp.|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN GI15-225	March 28, 2017	July 2019	January 2020	April 4, 2017		April 3, 2019	Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT03099564
128	NCT00863122	Concentration and Activity of Lapatinib in Vestibular Schwannomas		Completed	Has Results	Vestibular Schwannoma|NF2|Neurofibromatosis 2|Acoustic Neuroma|Auditory Tumor	Drug: lapatinib	Median Steady-state Lapatinib Plasma Concentrations at the Time of Surgical Resection|To Assess Whether Lapatinib Can Reach a Minimum Tumor Concentration Level of >3uM in VS After Oral Dosing.|Assess the Level of ErbB2 Phosphorylation in VS.|Assess Markers of Tumor Proliferation and Cell Death in VS After Exposure to Lapatinib.|Explore the Difference in the Concentration of Lapatinib Achieved in NF2-related Versus Idiopathic VS.|Perform NF2 Gene Mutation Analysis Via Exon Scanning and MLPA as Well as Protein Expression in All VS and Explore Differences Between Sporadic and NF2 Related VS.	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|The Children's Tumor Foundation|GlaxoSmithKline|New York University|Ohio State University|House Research Institute|Washington University School of Medicine|Weill Medical College of Cornell University|Massachusetts General Hospital	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	26	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	J0867|NA_00020841	June 2009	August 2014	August 2014	March 17, 2009	November 26, 2018	February 27, 2019	House Reserach Institute, Los Angeles, California, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University Medical Center, Saint Louis, Missouri, United States|New York University Medical Center, New York, New York, United States|Weil Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States|Ohio State University Medical Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT00863122
129	NCT03993821	Burosumab for CSHS		Not yet recruiting	No Results Available	Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)|Epidermal Nevus Syndrome	Drug: Burosumab	Serum Phosphorus change|Changes in 1,25(OH)2-Vitamin D|Changes in tubular reabsorption of phosphate (TRP)|Changes in TmP/GFR (the ratio of renal tubular maximum phosphate reabsorption rate to glomerular filtration rate|Biomechanical Marker|6-minute walk test|Sit-to-Stand test (STST)|Brief Pain Inventory (BPI)|Brief Fatigue Inventory (BFI)|SF36 item short health survey (SF-36)|PROMIS Pain Intensity|PROMIS Pain Interference|PROMIS Physical Function with Mobility Aid|PROMIS Fatigue	Laura Tosi|Children's Research Institute|Ultragenyx Pharmaceutical Inc	All	Child, Adult, Older Adult	Early Phase 1	1	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	IRB 11746	August 2019	August 2020	August 2021	June 21, 2019		June 21, 2019			https://ClinicalTrials.gov/show/NCT03993821
